We are live on ! Find out more
OCUL icon

Ocular Therapeutix

168 hedge funds and large institutions have $1.22B invested in Ocular Therapeutix in 2024 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 42 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 16

43% more funds holding in top 10

Funds holding in top 10: 710 (+3)

30% more capital invested

Capital invested by funds: $940M → $1.22B (+$280M)

12% more funds holding

Funds holding: 150168 (+18)

1.07% more ownership

Funds ownership: 88.69%89.76% (+1.1%)

14% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 49

26% less call options, than puts

Call options by funds: $2.34M | Put options by funds: $3.17M

Holders
168
Holders Change
+18
Holders Change %
+12%
% of All Funds
2.41%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.14%
New
34
Increased
42
Reduced
49
Closed
16
Calls
$2.34M
Puts
$3.17M
Net Calls
-$821K
Net Calls Change
+$1.27M
Name Holding Trade Value Shares
Change
Change in
Stake
PWM
176
Palumbo Wealth Management
New York
-$86.6K -12,667 Closed
DFCM
177
Dark Forest Capital Management
Puerto Rico
-$84.7K -12,383 Closed
QT
178
Quantbot Technologies
New York
-$74.1K -10,834 Closed
AG
179
Algert Global
California
-$69K -10,114 Closed
I
180
InceptionR
California
-$69K -10,087 Closed
ACA
181
Atlas Capital Advisors
Wyoming
-$34.2K -5,000 Closed
Comerica Bank
182
Comerica Bank
Texas
-$1.6K -234 Closed
PNC Financial Services Group
183
PNC Financial Services Group
Pennsylvania
-$725 -106 Closed
C
184
Covestor
United Kingdom
-$82 -10 -42%

OCUL Hedge Fund Activity: Q3 2024 in Review

168 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2024, worth a combined $1.22B — up 30% from $940M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new OCUL positions and 16 closed out — a net gain of 18 holders — while 42 added to existing stakes and 49 trimmed.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $23.3M. The largest seller was Logos Global Management, cutting an estimated $13.6M.

  • 168 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2024, up from 150 in Q2 2024.
  • Funds reported $1.22B of Ocular Therapeutix stock for Q3 2024, up 30% quarter-over-quarter.
  • 34 funds opened new Ocular Therapeutix positions in Q3 2024 and 16 closed out, a net change of +18 holders.
  • The largest Ocular Therapeutix buyer in Q3 2024 was Assenagon Asset Management, an estimated $23.3M added.
  • The largest Ocular Therapeutix seller in Q3 2024 was Logos Global Management, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2024.